[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-disease-progression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-disease-progression":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100483871","phase-3-reducing-mortality-in-adults-with-advanced-hiv-disease-revive-100483871",false,"NCT05580666","Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial","REVIVE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Documented HIV infection\n3. CD4 count criteria:\n\n   i. CD4 count ≤ 100 cells\u002Fmm3 within past 4 weeks; or\n\n   ii. Documented CD4 nadir ≤ 100 cells\u002Fmm3 and complete interruption of ART for ≥ 6 months; or\n\n   iii. Documented CD4 count ≤ 100 cells\u002Fmm3 if ART-naive\n4. Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment\n\nExclusion Criteria:\n\n1. Contraindications to azithromycin:\n\n   i. Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or\n\n   ii. Personal or family history of QT-prolongation\n2. Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)\n3. Off-label azithromycin prophylaxis or requirement for prolonged (\\> 7 days) azithromycin (or macrolide) therapy","ALL","18 Years",{"count":20,"type":21},8000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.",[27],"HIV Disease Progression",[29,30,31,32],"Human immunodeficiency virus","Antiretroviral therapy","Azithromycin","Mortality","RECRUITING","2025-08-26",{"date":36,"type":37},"2025-09-03","ACTUAL",{"date":39,"type":37},"2023-05-08",{"date":41,"type":21},"2029-05-31",{"name":43,"class":44},"Population Health Research Institute","OTHER",52]